1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global eClinical Solutions and Software Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global eClinical Solutions and Software Market Analysis 2017-2021 and Forecast 2022-2032, By Solution
5.1. Introduction/Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Solution, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Solution, 2022-2032
5.3.1. Randomization & Trial Supply Management (RTSM)
5.3.2. Clinical Data Management System (CDMS)
5.3.3. Clinical Trial Management System (CLMS)
5.3.4. Electronic Clinical Outcome Assessment (eCOA)
5.3.5. Electronic Trial Master File (eTMF)
5.3.6. Electronic Data Capture
5.3.7. Others
5.4. Y-o-Y Growth Trend Analysis By Solution, 2017-2021
5.5. Absolute $ Opportunity Analysis By Solution, 2022-2032
6. Global eClinical Solutions and Software Market Analysis 2017-2021 and Forecast 2022-2032, By Delivery Mode
6.1. Introduction/Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Delivery Mode, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Delivery Mode, 2022-2032
6.3.1. Licensed Enterprise (on-premise) Solution
6.3.2. Cloud-based (SAAS) Solution
6.3.3. Web-hosted (on-demand) Solution
6.4. Y-o-Y Growth Trend Analysis By Delivery Mode, 2017-2021
6.5. Absolute $ Opportunity Analysis By Delivery Mode, 2022-2032
7. Global eClinical Solutions and Software Market Analysis 2017-2021 and Forecast 2022-2032, By Clinical Trial Phase
7.1. Introduction/Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Clinical Trial Phase, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Clinical Trial Phase, 2022-2032
7.3.1. Phase I
7.3.2. Phase II
7.3.3. Phase III
7.3.4. Phase IV
7.4. Y-o-Y Growth Trend Analysis By Clinical Trial Phase, 2017-2021
7.5. Absolute $ Opportunity Analysis By Clinical Trial Phase, 2022-2032
8. Global eClinical Solutions and Software Market Analysis 2017-2021 and Forecast 2022-2032, By End-use
8.1. Introduction/Key Findings
8.2. Historical Market Size Value (US$ Mn) Analysis By End-use, 2017-2021
8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End-use, 2022-2032
8.3.1. Contract Research Organization
8.3.2. Medical Device Companies
8.3.3. Pharma/biotech Companies
8.3.4. Hospitals & Clinics
8.3.5. Others
8.4. Y-o-Y Growth Trend Analysis By End-use, 2017-2021
8.5. Absolute $ Opportunity Analysis By End-use, 2022-2032
9. Global eClinical Solutions and Software Market Analysis 2017-2021 and Forecast 2022-2032, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific
9.3.5. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America eClinical Solutions and Software Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. U.S.
10.2.1.2. Canada
10.2.2. By Solution
10.2.3. By Delivery Mode
10.2.4. By Clinical Trial Phase
10.2.5. By End-use
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Solution
10.3.3. By Delivery Mode
10.3.4. By Clinical Trial Phase
10.3.5. By End-use
10.4. Key Takeaways
11. Latin America eClinical Solutions and Software Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Solution
11.2.3. By Delivery Mode
11.2.4. By Clinical Trial Phase
11.2.5. By End-use
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Solution
11.3.3. By Delivery Mode
11.3.4. By Clinical Trial Phase
11.3.5. By End-use
11.4. Key Takeaways
12. Europe eClinical Solutions and Software Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. Italy
12.2.1.3. France
12.2.1.4. U.K.
12.2.1.5. Russia
12.2.1.6. BENELUX
12.2.1.7. Rest of Europe
12.2.2. By Solution
12.2.3. By Delivery Mode
12.2.4. By Clinical Trial Phase
12.2.5. By End-use
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Solution
12.3.3. By Delivery Mode
12.3.4. By Clinical Trial Phase
12.3.5. By End-use
12.4. Key Takeaways
13. Asia Pacific eClinical Solutions and Software Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.1.4. Rest of Asia Pacific
13.2.2. By Solution
13.2.3. By Delivery Mode
13.2.4. By Clinical Trial Phase
13.2.5. By End-use
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Solution
13.3.3. By Delivery Mode
13.3.4. By Clinical Trial Phase
13.3.5. By End-use
13.4. Key Takeaways
14. Middle East and Africa eClinical Solutions and Software Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Turkey
14.2.1.4. Rest of Middle East and Africa
14.2.2. By Solution
14.2.3. By Delivery Mode
14.2.4. By Clinical Trial Phase
14.2.5. By End-use
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Solution
14.3.3. By Delivery Mode
14.3.4. By Clinical Trial Phase
14.3.5. By End-use
14.4. Key Takeaways
15. Key Countries eClinical Solutions and Software Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Solution
15.1.2.2. By Delivery Mode
15.1.2.3. By Clinical Trial Phase
15.1.2.4. By End-use
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Solution
15.2.2.2. By Delivery Mode
15.2.2.3. By Clinical Trial Phase
15.2.2.4. By End-use
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Solution
15.3.2.2. By Delivery Mode
15.3.2.3. By Clinical Trial Phase
15.3.2.4. By End-use
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Solution
15.4.2.2. By Delivery Mode
15.4.2.3. By Clinical Trial Phase
15.4.2.4. By End-use
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Solution
15.5.2.2. By Delivery Mode
15.5.2.3. By Clinical Trial Phase
15.5.2.4. By End-use
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Solution
15.6.2.2. By Delivery Mode
15.6.2.3. By Clinical Trial Phase
15.6.2.4. By End-use
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Solution
15.7.2.2. By Delivery Mode
15.7.2.3. By Clinical Trial Phase
15.7.2.4. By End-use
15.8. U.K.
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Solution
15.8.2.2. By Delivery Mode
15.8.2.3. By Clinical Trial Phase
15.8.2.4. By End-use
15.9. Russia
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Solution
15.9.2.2. By Delivery Mode
15.9.2.3. By Clinical Trial Phase
15.9.2.4. By End-use
15.10. BENELUX
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Solution
15.10.2.2. By Delivery Mode
15.10.2.3. By Clinical Trial Phase
15.10.2.4. By End-use
15.11. China
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Solution
15.11.2.2. By Delivery Mode
15.11.2.3. By Clinical Trial Phase
15.11.2.4. By End-use
15.12. Japan
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Solution
15.12.2.2. By Delivery Mode
15.12.2.3. By Clinical Trial Phase
15.12.2.4. By End-use
15.13. South Korea
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Solution
15.13.2.2. By Delivery Mode
15.13.2.3. By Clinical Trial Phase
15.13.2.4. By End-use
15.14. GCC Countries
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Solution
15.14.2.2. By Delivery Mode
15.14.2.3. By Clinical Trial Phase
15.14.2.4. By End-use
15.15. South Africa
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Solution
15.15.2.2. By Delivery Mode
15.15.2.3. By Clinical Trial Phase
15.15.2.4. By End-use
15.16. Turkey
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Solution
15.16.2.2. By Delivery Mode
15.16.2.3. By Clinical Trial Phase
15.16.2.4. By End-use
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Solution
16.3.3. By Delivery Mode
16.3.4. By Clinical Trial Phase
16.3.5. By End-use
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Advarra
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Signant Health
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Datatrak, Inc
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Clario
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Veeva Systems
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. IBM Watson Health
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Oracle Corporation
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Anju Software Inc
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Parexel International Corporation
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Ennov
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Medsharing
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Multihealth Group
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. Dassault Systemes
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.14. Arone
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.15. ALTENE Group
17.1.15.1. Overview
17.1.15.2. Product Portfolio
17.1.15.3. Profitability by Market Segments
17.1.15.4. Sales Footprint
17.1.15.5. Strategy Overview
17.1.15.5.1. Marketing Strategy
17.1.16. Datacapt
17.1.16.1. Overview
17.1.16.2. Product Portfolio
17.1.16.3. Profitability by Market Segments
17.1.16.4. Sales Footprint
17.1.16.5. Strategy Overview
17.1.16.5.1. Marketing Strategy
17.1.17. Evamed
17.1.17.1. Overview
17.1.17.2. Product Portfolio
17.1.17.3. Profitability by Market Segments
17.1.17.4. Sales Footprint
17.1.17.5. Strategy Overview
17.1.17.5.1. Marketing Strategy
